H.C. Wainwright Upgrades Sarepta to Neutral on Valuation Ahead of Q1 Results
H.C. Wainwright upgraded Sarepta Therapeutics (NASDAQ: SRPT) from Sell to Neutral with a new 12-month price target of $75. The […]
H.C. Wainwright Upgrades Sarepta to Neutral on Valuation Ahead of Q1 Results Read More »